Efanesoctocog alfa is a high-sustained factor (F)VIII replacement therapy for hemophilia A. The D'D3 domain of efanesoctocog alfa overcomes the von Willebrand factor–imposed half-life ceiling and...
Lire la suite

Bleeding complications are frequent under left ventricular assist device (LVAD) support. LVAD-associated high shear stress induces increased proteolysis of circulating von Willebrand factor (VWF), which...
Lire la suite

Long-term von Willebrand factor (VWF) prophylaxis is recommended for people with von Willebrand disease (VWD) who experience frequent and severe bleeds. However, repeated administration of VWF-containing...
Lire la suite

Multiple studies conducted between 1990s and 2010s reported increased rates of postpartum hemorrhage (PPH) among women with von Willebrand disease (VWD), even with specialized peripartum care. To generate contemporary data on pregnancy outcomes among women with VWD using a statewide database, the Utah Population Database. We included women with a first live singleton birth at Intermountain Health or University of Utah facilities from January 1, 2008,...
Lire la suite